Durvalumab and Oleclumab in Resectable PDAC (DORA)

University Health Network, Toronto

Status and phase

Enrolling

Phase 2

Conditions

Pancreatic Ductal Adenocarcinoma

Treatments

Drug: Oleclumab

Drug: Durvalumab

Study type

Interventional

Funder types

Other

Identifiers

NCT06060405

OZUHN-013

22-6031 (Other Identifier)

Details and patient eligibility

About

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.

Enrollment

22 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Weight ≥ 35 kg
Have a life expectancy ≥ 12 weeks
Have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).
Upfront resectable PDAC
Have adequate organ and marrow function required for the study
Baseline images taken prior to treatment must undergo central review
Participants must agree to use study approved methods to prevent pregnancy for study required period

Exclusion criteria

Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
Prior receipt of any immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1 including durvalumab antibodies and agents targeting CD73, CD39, or adenosine receptors, excluding therapeutic anticancer vaccines.
Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed.
Have a history of Grade 3 or greater thromboembolic events in the prior 3 months or thromboembolic event of any grade with ongoing symptoms.
Have prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.
Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with the following exceptions
- Vitiligo or alopecia
- Hypothyroidism not requiring systemic treatment or stable on hormone replacement
- Psoriasis not requiring systemic treatment
- Any chronic skin condition that does not require systemic therapy
Have known active hepatitis infection. Participants with a past or resolved Hepatitis B (HBV) infection are eligible. Participants positive for Hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection
Other invasive malignancy within 5 years.
Known allergy or hypersensitivity to investigational product formulations.
Active grade 3 or greater edema
Uncontrolled intercurrent illness
Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment with the following exceptions:
- Intranasal, topical, inhaled corticosteroids or local steroid injections
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
- Steroids as premedication for hypersensitivity reaction
Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment
Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery. Local are allowed, without needing to wait for the 28 day recovery period.
Are pregnant, lactating, or intend to become pregnant during their participation in the study
Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results